Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
Biotechs want to fulfill their mission to patients and build global enterprise value through international commercialization, while preserving strategic optionality.
Several value-creating activities must be identified and performed before a final go-direct or partner decision is taken. Most do not have the relevant experience for this work.
ICE Biopharma can identify and execute pre-commercialization steps to preserve strategic optionality, limiting Biotech resource commitment and distraction from US launch priorities.



Evaluation of Market Potential, Competition, Pricing and Reimbursement, Organisation Build - all leading to a Business Case

Assessment of Different Commercialization Pathways from both Strategic and Financial perspectives to Identify the most vialbe Option; Partner Identification

Pricing & Reimbursement Strategy and advice on GVD Development / Cost Effectiveness Modelling / RWE

Gap Analysis, Input on Scientific Advice, MAA and Labeling Strategy, Dossier Submission and Response Guidance

Goods & Money Flow, License Mapping, QA/QC, Legal Entities, Inter-Company and Financial/Customs/VAT Set-up

Early Access Program Strategy, Eligibility Assessment, Business Case Generation

Clinical Program Advisory Services, KOL Mapping and Engagement, Congresses Publications, Communications

Creation of Comprehensive, Cross-Functional Action Plans and Processes to Achieve a Smooth and Timely Product Launch

Development of the Organizational Staffing Plan at HQ, Regional Hub(s) and Cluster/Countries Levels / Define Business Gating Milestones to Deploy Resources

Identifying and Implementing Strategic Actions that reate Value under any Future Market Scenario